Board Recommended final dividend of Re.0.60/- per equity shares of face value of Re.1/- each
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Shilpa Medicare's Board has recommended a final dividend of ₹0.60 per equity share (60% payout on ₹1 face value) for FY 2025-26, subject to shareholder approval at the AGM. The company reported strong financial performance with standalone net profit jumping 96% year-on-year to ₹13,297 lakhs, while consolidated net profit rose 211% to ₹24,333 lakhs. Consolidated revenue from operations grew 20% to ₹1,53,887 lakhs. The paid-up share capital doubled from ₹978 lakhs to ₹1,956 lakhs compared to the previous year, indicating a 1:1 bonus issue was completed. The company also announced plans to shift its registered office from Karnataka to Maharashtra and acquire a 28% stake in Neo Green Power Project Private Limited for ₹4.44 crore to meet captive power requirements.
The dividend maintains a 60% payout ratio consistent with prior year, signalling management confidence in sustained earnings growth. The near-doubling of net profit provides strong fundamental support for the stock. However, the absolute dividend amount remains modest at ₹0.60 per share.